|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.180 USD | -4.95% |
|
-23.15% | -65.19% |
| 07-08 | Seres Therapeutics Announces Early Clinical Data Showing Potential For SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis | CI |
| 07-08 | Seres Therapeutics, Inc. - Special Call |
| Market Cap | 50.16M 43.85M 40.55M 37.21M 70.42M 4.83B 71.65M 484M 190M 2.36B 188M 184M 8.15B | P/E 2026 * |
-0.69x | P/E 2027 * | -0.79x |
|---|---|---|---|---|---|
| Enterprise Value | 50.16M 43.85M 40.55M 37.21M 70.42M 4.83B 71.65M 484M 190M 2.36B 188M 184M 8.15B | EV / Sales 2026 * |
3.9x | EV / Sales 2027 * | 140x |
| Free-Float |
88.22% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Seres Therapeutics, Inc.
| 1 day | -4.95% | ||
| 1 week | -23.15% | ||
| Current month | -34.35% | ||
| 1 month | -13.23% | ||
| 3 months | -41.34% | ||
| 6 months | -67.54% | ||
| Current year | -65.19% |
| 1 week | 5.04 |  | 6.12 |
| 1 month | 5.04 | | 8.25 |
| Current year | 5.04 | | 16.42 |
| 1 year | 5.04 | | 29.98 |
| 3 years | 5.04 | | 105.8 |
| 5 years | 5.04 | | 420 |
| 10 years | 5.04 | | 770 |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Kender
CEO | Chief Executive Officer | 70 | 01/03/2026 |
Ann Thorell
CEO | Chief Executive Officer | 58 | 31/07/2025 |
Matthew Henn
PSD | President | 51 | 01/03/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Richard Kender
CHM | Chairman | 70 | 01/03/2026 |
Eric Shaff
BRD | Director/Board Member | 50 | 14/01/2019 |
Dennis Ausiello
BRD | Director/Board Member | 80 | 31/03/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 08/07/26 | Free | Chairperson | 25,000 | 0.2582% | ||
| 08/07/26 | Free | Director | 6,500 | 0.0671% | ||
| 08/07/26 | Free | General Counsel | 7,500 | 0.0774% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.95% | -23.15% | -62.92% | -94.27% | 50.16M | |
| -3.42% | +4.90% | +61.15% | +87.70% | 55.98B | |
| -1.68% | -3.43% | +50.29% | +68.56% | 53.69B | |
| -2.14% | -9.13% | +2.74% | +421.65% | 23.29B | |
| -0.47% | -1.53% | -18.61% | -15.41% | 23.15B | |
| -5.95% | -2.58% | +30.67% | -9.47% | 20.58B | |
| -1.81% | -0.75% | +30.55% | -30.96% | 17.76B | |
| -4.55% | -1.95% | +192.65% | +349.58% | 16.09B | |
| -6.91% | -5.83% | +26.53% | +644.30% | 15.93B | |
| +0.23% | -2.49% | +24.26% | +187.16% | 14B | |
| Average | -3.17% | -2.71% | +33.73% | +160.88% | 24.05B | |
| Weighted average by Cap. | -2.82% | -0.89% | +44.86% | +148.90% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 12.86M 11.24M 10.39M 9.54M 18.05M 1.24B 18.37M 124M 48.69M 605M 48.29M 47.23M 2.09B | 358K 313K 289K 266K 503K 34.5M 511K 3.45M 1.36M 16.85M 1.34M 1.31M 58.16M |
| Net income | -70.97M -62.03M -57.37M -52.64M -99.63M -6.84B -101M -684M -269M -3.34B -267M -261M -11.53B | -99.82M -87.26M -80.69M -74.05M -140M -9.62B -143M -962M -378M -4.7B -375M -367M -16.22B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/07/26 | US$5.180 | -4.95% | 84,138 |
| 15/07/26 | US$5.450 | +2.16% | 30,991 |
| 14/07/26 | US$5.335 | -5.07% | 223,167 |
| 13/07/26 | US$5.620 | -8.02% | 333,663 |
| 10/07/26 | US$6.110 | -9.35% | 154,449 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MCRB Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
